Harvard cancer research
Notice informs the biomedical and health services research communities of changes to grant application form and application guide instructions for due dates on or after january 25, /hcc's breast cancer spore has released rfa's for its career enhancement and developmental research project awards, with applications due on december 1, 2017. Hcc's newest spore has released rfa's for its career enhancement and developmental research project awards, with applications due on december 1, 2017. Training and academic year, the dana-farber/harvard cancer center and the hms/hsdm office of postdoctoral fellows will offer the nih-supported national research mentoring network (nrmn) curriculum to provide evidence-based... Of global for external chresearch departments, centers, initiatives and ay library of researcher rvard medicine up for email make a gift gn steering -farber cancer /about hms/hms affiliates/dana-farber cancer hms facts & figurespast deans of the faculty of 's cornerdean's report 2017-2018contacts and t profiles2015-2016 md student shipboard of & culturehms community ty & emergency tion and entrepreneurshipinnovation in ity task forceabout the task ytimeline of affiliatesbeth israel deaconess medical children's m and women's dge health -farber cancer d pilgrim health care diabetes baker's children's husetts eye and husetts general auburn ing rehabilitation boston healthcare affiliate: the forsyth keeping connectedharvard medicine memoriamdaniel d. Albright, md ’31 : 70 years of women at te and external ntly asked tionclass day accreditationthe lcme accreditation faq and dana-farber cancer -farber is committed to providing cancer patients with the best cancer care possible today, while advancing tomorrow’s cures through intensive basic and clinical research. We are a leader in the development of national cancer treatment guidelines and improving the quality and effectiveness of cancer care. Our areas of expertise include breast cancer, skin cancer, gynecological cancers, lung cancer, stem cell transplants, and cancer clinical -farber is a principal teaching affiliate of harvard medical school and a clinical partner of brigham & women’s hospital for adult cancer care and boston children’s hospital for pediatric cancer and blood disorders and care. As a founding member of the dana-farber/harvard cancer center, a national cancer institute-designated comprehensive cancer center, and a member of the national comprehensive cancer network, dana-farber is one of the world’s leading cancer centers and is consistently the top-rated cancer hospital in new dana-farber's website ». 2017 by the president and fellows of harvard scienceoverviewmaking discoveriesmoving discoveriesour peoplenameresearch arealocationleadershipour storysuccess storiesnews and reportsabout usour brandguidelinesmessage brugge was recently awarded the american cancer society medal of honor. Brugge in this video tribute to her life and research, courtesy of demetri describes developments in sarcoma research that are contributing to advances in the development of targeted and epigenetic drugs, and even : the ludwig center is housed within the dana-farber cancer institute with operational units extending throughout leading laboratories and hospitals affiliated with the harvard medical school in boston, massachusetts, usa, including brigham and women's hospital, children's hospital of boston and massachusetts general hospital, as well as the broad institute in cambridge, brugge was recently awarded the american cancer society medal of honor. Brugge in this video tribute to her life and research, courtesy of demetri describes developments in sarcoma research that are contributing to advances in the development of targeted and epigenetic drugs, and even : the ludwig center is housed within the dana-farber cancer institute with operational units extending throughout leading laboratories and hospitals affiliated with the harvard medical school in boston, massachusetts, usa, including brigham and women's hospital, children's hospital of boston and massachusetts general hospital, as well as the broad institute in cambridge, center at ludwig center at harvard investigates and seeks to overcome the resistance of cancer cells to current and emerging therapies. While significant advances have been made in the treatment of cancer, both primary and acquired resistance remain major challenges to reducing the burden of cancer. Basic scientists and physician-investigators from across the harvard medical school work together at our center to study how changes in the genomes of cancer cells and other unique factors within the tumor and its local environment converge to generate such resistance. We integrate orthogonal perspectives, tools and investigative strategies across disciplines to address these questions and devise new approaches to maximize the impact of anticancer here to download the powerpoint slides presented at the informational sessions across harvard and learn more about the collaborative cancer research challenge at center at orsteamresearch biology, tumor academic career has been focused on understanding the fundamental mechanisms of cancer growth and lab has modeled cancer development using a cell culture system in which cells are able to organize into three-dimensional structures that resemble the organization of normal tissue or the distorted microenvironment of tumors. It has also highlighted the critical role of cancer-causing oncogenes in controlling both cell death and metabolic impairments associated with this step in tumor development. Most recently, my laboratory interests have evolved to understanding the resistance mechanisms by which tumor cells escape the impact of cancer therapy to allow us to develop new strategies which can overcome resistance and significantly improve current and emerging cancer therapies. Have been on the faculty of harvard medical school since 1997, and in addition to my role as co-director of the ludwig center, i serve as chair of the department of cell biology at harvard medical ionphd, baylor college of medicine, dallas, texas, , northwestern university, chicago, ementsinvestigator, howard hughes medical an cancer society research career recognition award from the american society of cell , national academy of , institute of , american academy of arts and eutics, academic career has been devoted to applying novel insights from fundamental molecular biological and biochemical research to the problems of human cancer to develop rationally targeted anti-cancer therapeutics in an academic research program focuses heavily on translational and clinical science that will accelerate the development of novel experimental therapeutic agents targeting specific signaling pathways in molecularly defined subtypes of cancer, with a major focus on mesenchymal neoplasms and most noteworthy successes have changed the standards of care for patients with sarcomas and gastrointestinal stromal tumors (gist), leading to the fda and worldwide regulatory approval of imatinib (gleevec in 2002), sunitinib (sutent in 2006) and regorafenib (stivarga in 2013) for gist, as well as trabectedin (yondelis outside the usa in 2007) and pazopanib (votrient in 2012) for other sarcomas. The academic insights that we have developed in sarcomas are also highly relevant to translational and clinical investigation in more common forms of cancer, and our program is expanding across harvard and the broad institute to build long-term research strategies to target cancers based on genomic, metabolomic, and immunobiologic criteria of vulnerability based on defined molecular addition to serving as the co-director of the ludwig center, i am an associate director for clinical sciences at the dana-farber/harvard cancer center, the nci-designated comprehensive cancer center of harvard university. Through these roles, i am able to link basic, translational and clinical research initiatives across multiple departments to bring together new collaborations focused on experimental therapeutics within the ludwig cancer research , stanford university school of medicine, stanford, california, , biochemical sciences, harvard college, cambridge, massachusetts, international fellowship, école de medicine, biochemistry and endocrinology, université de besançon, france, s. Evans award in medicine, university of washington, seattle, l-myers oncology basic research grant award, an cancer society career development award, n and johnson foundation focused giving award, j freireich award in clinical cancer research, md anderson cancer center, texas, a foundation of america, nobility in science award, w. Morse research award, dfci, family outstanding achievement award, dfci, der bodini foundation prize for scientific excellence in medicine, funds for cancer research award for developmental therapeutics, eutics, tumor i am an associate professor of medicine at harvard medical school and co-director of the cancer cell biology program. My specific expertise is in the ras pathway, one of the most commonly deregulated signaling pathways in human cancer. My lab studies this pathway in many tumor types, including sarcomas, glioblastomas, prostate, lung and breast cancers. We have extensively investigated the nf1 tumor suppressor, a ras-regulatory gene that is mutated in neurofibromatosis, a familial cancer syndrome for which there are few therapies. We have also been studying nf1-related genes and have identified two new tumor suppressors within this family, and found that one of them underlies metastatic prostate cancer. We’ve discovered that mutations in this gene drive a broad spectrum of tumor-types, and that inactivation of a third gene within this family promotes breast cancer. I have received several awards for my research, including the translational science award of the children’s tumor foundation and the innovative research idea prize, national neurofibromatosis eutics, my primary research interest is in cancer immunotherapy, particularly the development of immune checkpoint inhibitors. I am director of the melanoma center and the center for immuno-oncology at dana-farber/brigham and women's cancer center and an assistant professor of medicine at harvard medical school.
I received my md from cornell university medical college in 1992, and completed my training in internal medicine at the hospital of the university of pennsylvania and my medical oncology training at dana-farber cancer institute, where i joined the faculty in immunology, my research in the 1980s focused on the discovery of molecules uniquely expressed on human b cells using monoclonal antibodies. Serve as the executive dean for clinical and translational research at the harvard medical school, where i direct the harvard catalyst, which serves as the nih-funded clinical and translational science center for harvard , queens college of the city university of new york, , harvard medical school, biology, genomics, stem i am a professor in the department of pathology at massachusetts general hospital and harvard medical school and a member of the broad institute, where i co-direct the epigenomics program. My research focuses on epigenetics—changes in gene activity governed by influences outside the genes themselves. Specifically, we focus on how modifications to chromatin (a term for dna and its protein scaffolding) contribute to mammalian development and human cancer. My group has helped uncover key epigenetic mechanisms in pluripotent stem cells, developed experimental systems to identify enhancer “switches” in the human genome that coincide with sequence variants associated with common diseases, and contributed significantly to the characterization of epigenetic aberrations that underlie certain forms of cancer. I did my postdoctoral research at harvard university with stuart schreiber and collaborated extensively with eric lander. My honors and awards include a howard hughes postdoctoral research fellowship for physicians, a career award in the biomedical sciences from the burroughs wellcome fund and election to the american society for clinical eutics, tumor my primary field of research is translational cancer biology. I am particularly interested in combining classic mouse genetics and experimental therapeutics to address basic mechanism and genetic questions related to clinical cancer treatment; identify and evaluate potential treatment methods; and molecular stratification of patients for targeted , biochemistry, dartmouth college, my laboratory is internationally known for its contributions to the study of dna damage and repair, particularly the elucidation of a repair pathway whose dysfunction underlies an inherited genetic disorder known as fanconi anemia (fa). This disease is characterized by bone marrow failure, cancer susceptibility and cellular hypersensitivity to dna crosslinking agents. We have helped unravel the components and mechanisms of the fa pathway, and demonstrated that one of the fa genes (fancd1) is identical to the breast cancer gene, brca2. We continue to explore the relationship between chromosome instability and cancer, focusing on the role of the fa pathway in cancers and the identification of biomarkers associated with it for cancer therapy. Fuller american cancer society professor of radiation oncology at harvard medical school, and director of the center for dna damage and repair at the dana-farber cancer institute. I am a fellow of the american association for the advancement of science and a member of the national cancer institute's board of scientific counselors in basic sciences. I received my md in 1983 from harvard medical school and completed my residency in pediatrics at the children’s hospital of philadelphia. As a postdoctoral fellow at the whitehead institute of biomedical research in cambridge, massachusetts, i cloned the erythropoietin receptor, a protein known to rescue red blood cell progenitors from programmed biology, my research is focused on the development and clinical application of optical microscopy and spectroscopy tools, with an emphasis on the ultrasensitive detection of molecular markers, label-free imaging of tissues and the imaging and quantification of tissue oxygenation. In chemistry from harvard university and completed my postdoctoral training under the supervision of tayyaba hasan and johannes de boer in the application of advanced microscopy to cancer research. I am an assistant professor at the wellman center for photomedicine of harvard medical school at the massachusetts general hospital and a planning group member of the harvard ludwig center. I am taking a lead role in developing the center for targeted cancer biology, i study the role of chromatin regulation in human cancer, with a focus on the structure and function of the mammalian swi/snf (or baf) family of chromatin remodeling complexes, which are mutated in more than a fifth of human cancers. My lab has elucidated the molecular mechanisms that drive human synovial sarcoma, linking the hallmark feature of these cancers—the aberrant ss18-ssx fusion protein—to baf complex dysfunction and the development of cancer. I am an assistant professor of pediatric oncology at the dana-farber cancer institute and harvard medical school and a member of the broad institute of mit and harvard. In cancer biology from the stanford university school of medicine, and have received the nih director’s new innovator award, the pew-stewart scholar in cancer research award, and was named one of forbes top 30-under-30 in science and biology, i received my md and phd from the university of chicago. I then completed clinical training in internal medicine at brigham and women's hospital, boston, after which i walked across the street to do a fellowship in hematology and oncology at dana-farber cancer institute. This is where i was introduced to apoptosis and the bcl-2 family proteins as a post-doctoral researcher in the laboratory of the late stanley korsmeyer. In 2004, i became an independent investigator at the harvard medical school and the dana-farber cancer institute, where i am now an associate professor of medicine. My lab studies how apoptosis can be evaded, particularly in cancer cells, and how this evasion may be detected and targeted. Key to these studies is a novel assay we call bh3 profiling, which can detect the blocks cancer cells use to evade apoptosis and cells that are dependent on bcl-2. The laboratory will be testing whether bh3 profiling can be used as a predictive biomarker in clinical cancer therapy. I am an investigator of the howard hughes medical institute and a professor of systems biology and of medicine at harvard medical school.
I received my md (cum laude) from the harvard-mit division of health sciences and technology, where my thesis research focused on mitochondrial energetics. I have received a number of honors, including a macarthur foundation fellowship, the judson daland prize of the american philosophical society, the keilin medal of the biochemical society, a padma shri from the government of india, and election to the national academy of i am a computational biologist, specializing in epigenomics and cancer genomics, particularly the computational and statistical analysis of genomic data. We analyze epigenome and whole-genome sequencing datasets from cancer and other diseases, using high-throughput sequencing technology. We have also been involved in the cancer genome atlas (tcga) project, which has performed comprehensive genomic characterization of nearly 10,000 cancer samples. I originally trained in applied mathematics at harvard and caltech, and became interested in molecular biology and genomics during a postdoctoral fellowship at the harvard school of public health. Today, i am an associate professor at harvard medical school, where i co-direct the doctoral program in bioinformatics and integrative genomics. I live in cambridge, massachusetts, with my wife, who is on the piano faculty at the new england conservatory preparatory school, and spend most of my free time with my two beautiful biology, i am a professor of medicine at dana-farber cancer institute of harvard medical school and an internationally recognized leader in the breast cancer field. Research in my laboratory is dedicated to the molecular analysis of human breast cancer, with the goal of identifying differences between normal and cancerous breast tissue, and using this information to improve the clinical management of patients. We have also had some success in the clinical translation of our findings, notably in the clinical trials of jak and bet bromodomain inhibitors for the treatment of triple negative breast cancer. I have received numerous awards for my work, including the paul marks prize for cancer research in 2011 and the 2012 aacr outstanding investigator award for breast cancer i joined the harvard community in 2016 as director of the cbio center at the dana-farber cancer institute (within the department of biostatistics and computational biology), professor of cell biology at harvard medical school, and associate member of the broad my time as a postdoctoral researcher, i was inspired by the first completely sequenced genome to switch fields from theoretical physics to theoretical biology. I later founded two computational biology departments—at the european molecular biology laboratory and memorial sloan kettering cancer center—and co-founded the research branch of the european bioinformatics institute and a biotech startup with millennium research focuses on solving biological problems using quantitative methods from bioinformatics, statistical physics, data sciences, statistics, computer science, and mathematics. We apply these computational methods to build predictive network models of molecular and cell-cell interactions, to support cancer precision medicine and to make discoveries in structural and evolutionary biology. We also build tools for the research and clinical communities, such as the cbioportal to analyze large genomics datasets and a platform to enable oncologists to more efficiently match patients to genomically informed clinical cells, cell biology, i am a practicing hematologist/oncologist and the gerald and darlene jordan professor of medicine at harvard university. We have also shown how such niche interactions can be manipulated and altered, studies that have resulted in two clinical trials in the use of stem cells to treat blood cancers. I am particularly interested in applying my laboratory work to the treatment of cancer and am the founding director of the center for regenerative medicine at the massachusetts general hospital, i also co-founded and co-direct the harvard stem cell institute and the harvard university department of stem cell and regenerative biology. I am a member of the institute of medicine of the national academies of science, the board of external experts for the national heart, lung and blood institute and a former member of the national cancer institute’s board of scientific counselors. I began work on micrornas as a postdoctoral fellow in gary ruvkun’s laboratory at harvard medical school, where i co-discovered the second known microrna, let-7i, and the first human microrna. My lab at bidmc continues to explore micrornas and has been involved in developing let-7 and a second microrna, mir-34, as novel cancer therapeutics (with mir-34 now independently in phase i clinical trials). My group is also working on identifying novel single-base sequence variations (snps) in the non-coding portions of the genome, with an eye to identifying the next generation of actionable targets in cancer. I was an ellison medical foundation senior scholar, and received the heath award from the md anderson cancer center in ing, tumor my laboratory studies a number of signal transduction pathways central to cancer. We have focused on transcription factors of the nfat family, and shown that they are functionally active in cancer cells, and required for promoting the invasion of carcinoma cells. We are currently evaluating the importance of nfat activity in breast cancer progression in vivo, and deciphering the transcriptional targets of nfat in breast cancer cells. We are also investigating the mechanisms by which the pi 3-kinase and akt signaling pathway regulates breast cancer progression. Our studies have focused on the role of the akt kinase in modulating breast cancer progression, and we have made some very surprising findings in this area. Another major research focus in the laboratory is the function of the serine/threonine kinase pkd (protein kinase d) in cancer cell biology. I received my phd from the national institute for medical research, london, uk, in 1991 and conducted post-doctoral research in the laboratory of prof. In 2014, i was appointed chief of the division of signal transduction in the departments of pathology and the medicine and cancer center at eutics, sarcomas constitute a heterogeneous family of rare tumors with mesenchymal cell origin. Our research goals have been to create reliable laboratory models of sarcoma from patient-derived specimens, to identify novel oncogenic pathways in these tumors and to test novel targeted compounds according to the identified alterations.
These novel drugs specifically targeted to the genetic alteration in the tumor might provide more effective and less toxic treatment options for patients with , biochemistry and molecular biology, university of chicago, with honors, pritzker school of medicine, university of chicago, with distinction, biology, swarthmore college, and stephen fine award for outstanding teaching in cancer medicine, dfci, nding teaching award, harvard university, d medical school class of 2001 award for distinction in teaching, harvard medical school, biology, my career has focused on cancer biology, most importantly the control of cell division and the molecular and cellular changes that initiate and maintain the cancerous transformation. I served at cold spring harbor laboratory from 1982 to 1990, later serving as scientific director for the massachusetts general hospital cancer center and as associate director for science policy at the national cancer institute, where i helped direct u. I have also served as professor and chair of the department of biological chemistry and molecular pharmacology at the harvard medical school and associate director of the dana-farber/harvard cancer center. Most recently, in addition to my work at harvard medical school as one of the recipients of the virginia and daniel k. Harold varmus at the national cancer institute to help our country address many of the critical challenges and opportunities facing cancer research and ms from the university of , imperial cancer research fund, london, ship, national academy of sciences, usa, ship, institute of medicine, , american academy of arts and of honor, american cancer ing, my laboratory is primarily focused on determining the role of notch signaling in t-cell acute lymphoblastic leukemia (t-all) and other cancers. Notch receptors participate in a signaling pathway that controls normal differentiation and many other fundamental cellular processes, and dysregulated notch signaling has been implicated in virtually all the pathological hallmarks of cancer, as well as in clinically important phenomena such as drug resistance. I have received many awards for my contributions to cancer research and am a professor of pathology at brigham and women’s hospital and harvard medical school, chief of hematopathology at brigham and women’s hospital and co-leader of the cancer research center of the brigham biomedical research institute. From the university of michigan at ann my laboratory explores the factors underlying the hormone-dependence of breast and prostate cancers. I am today director of the center for functional cancer epigenetics at the dana-farber cancer institute and professor of medicine at harvard medical school. Following a fellowship in medical oncology at dana-farber and postdoctoral research at mit, i joined the staff of dana-farber and the faculty of harvard medical eutics, my research is focused on studying neuroendocrine cancers, in particular small cell lung cancer and neuroendocrine pancreatic cancer. The focus of my research is to elucidate the sequential accumulation of genetic and epigenetic lesions upon introduction of the initial transforming events in the mouse genome. Mapping these events will allow us to identify treatment targetable events and accelerate drug , copenhagen university, copenhagen, denmark, scholarship from copenhagen university, phd studies at copenhagen university hospital, ctoral fellowship from the danish cancer society, postdoctoral studies at dana-farber cancer institute, boston, usa, i am the gregor mendel professor of genetics and medicine at harvard medical school and an investigator with the howard hughes medical institute. I am a senior fellow of the american cancer society, a pew scholar, and a howard hughes investigator. I have received numerous awards for my research, including the 2015 albert lasker basic medical research award, and have been elected to the national academy of sciences, the american academy of arts and sciences, and the institute of biology, my laboratory studies the role played by the sir2 (silent information regulator) family of proteins, or sirtuins, in metabolism and disease. These proteins, which are found in mitochondria—the power plants of the cell—have been implicated in aging, metabolic diseases and cancer. Our research integrates biochemistry, proteomics, cell biology and mouse genetics, and could lead to novel therapies for a wide spectrum of human diseases. I began my research on sir2 while conducting postdoctoral research at mit, after obtaining my doctorate in biochemistry from the university of wisconsin, madison. I am an associate professor in the department of cell biology at harvard medical school and a member of the paul f. Glenn laboratories for biological mechanisms of biology, the overarching goal of my research is to dissect the pathophysiology of the vascular and extra-vascular components of tumors, to determine the role of tumor-host interactions in tumor biology and, ultimately, to translate this knowledge into improved cancer detection, prevention and treatment in humans. Our work has provided unprecedented molecular, cellular, anatomical and functional insights into the vascular, interstitial and cellular barriers to cancer treatment. It has also led to more than 25 clinical trials for various cancers and the development of new approaches to cancer therapy. We have validated this concept in glioblastoma, lung and breast cancer patients receiving antiangiogenic therapy and, in the process, discovered potential biomarkers of tumor escape from these therapies. Now we are exploring novel strategies to improve immunotherapy of cancer by “normalizing” blood vessels and the extracellular matrix. Cook professor of radiation oncology (tumor biology) at harvard medical school and director of the edwin l. I have received numerous honors for my research, including the 2013 national medal of science, awarded in 2016. We expect that our studies will shed light on the subcellular decision-making processes of healthy and cancerous cells alike, and help explain why cells vary so dramatically in their response to identical drugs. The p53 protein is very frequently inactivated in human cancer, and the regulatory circuit in which it is involved is functionally inactivated in almost all cancers. I then spent a year at harvard’s bauer center for genomics research and, in the fall of 2004, joined the department of systems biology at harvard medical school, where i am today a i am a professor of computational biology at the dana-farber cancer institute, and at the harvard t.
My laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy and the emergence of drug resistance. We study the genetic and epigenetic changes that drive cancer, the order of oncogenic mutations that initiate and sustain tumorigenesis and the “hows and wheres” of these processes. From the department of organismic and evolutionary biology at harvard university, after which i was awarded a fellowship from the harvard society of fellows. From 2007 to 2010, i was an assistant professor in the computational biology program at memorial sloan-kettering cancer center. I am now the director of the dana-farber cancer institute physical sciences-oncology center and the center for cancer evolution. I have received, among other honors, the theodosius dobzhansky prize of the society for the study of evolution, the alice hamilton award from harvard university, and the vilcek prize for creative promise in biomedical biology, signaling, i am a clinical oncologist and a cancer geneticist at harvard medical school, where i currently hold the reisman endowed chair of medicine and am a professor of pathology. My laboratory has made seminal contributions to our understanding of the molecular mechanisms and genetics of leukemias, lymphomas, and the modeling of these cancers in the mouse. Today, i also serve as director of the cancer center and the cancer research institute at the beth israel deaconess medical center (bidmc), which i joined in 2007 from memorial sloan kettering. I am also director of the cancer genetics program and head the division of genetics in the department of medicine at bidmc. In 2011, i received the pezcoller foundation-aacr international award for cancer i am the maragaret m. Dyson professor of pediatric oncology at harvard medical school, where i am also a professor of cell biology. Our work on cytoskeletal dynamics is focused on the mechanism of chromosome segregation in normal cells and cancer cells. I completed my fellowship in hematology and oncology at the children's hospital, in boston and did postdoctoral research at the whitehead institute of the massachusetts institute of technology in the laboratory of gerald fink. The hsf1 transcriptional program differs when activated in cancer versus when it is activated in response to heat shock; we are exploring how and why in a variety of tumor types. I am an assistant professor in pathology at harvard medical school, and practice surgical and molecular pathology at brigham and women’s hospital and boston children’s hospital, specializing in the diagnosis of brain tumors. My lab helped discover and elucidate the functions of key t cell costimulatory pathways, including the immune-inhibitory functions of the ctla-4 and pd-1 pathways, which have become highly effective targets for cancer immunotherapy. We study how costimulatory pathways prevent auto-immunity and regulate antimicrobial and antitumor immunity, and are investigating potentially new therapies for autoimmune diseases, chronic viral infections, and cancer. I am the george fabyan professor of comparative pathology and co-director of the evergrande center for immunologic diseases and the harvard institute of translational immunology at harvard medical school, where i also received my m. I have published over 300 papers and was listed by thomson reuters as one of the most highly cited researchers (top 1%) in 2014. Coley award for distinguished research in tumor immunology in 2014 for my contributions to the discovery of pd-1 biology, my laboratory explores the control of eukaryotic cell division, focusing on the protein machinery that segregates chromosomes during mitosis and on the signaling networks that regulate cell proliferation and death, defects in which can lead to cancer. We focus on two main areas of research: the study of the genomic instability that underlies cancer; and a systems approach to charting mammalian cell signaling and response to anti-cancer drugs. I am the otto krayer professor of systems pharmacology at harvard medical school (hms) and director of the center for cell decision processes, an nih center of excellence in systems biology. As a graduate student at the harvard medical school, working in the laboratory of h. Later, while at the cardiovascular research center, massachusetts general hospital, i demonstrated that an enzyme later named caspase-1 is a functional homologue of c. After moving to the department of cell biology at harvard medical school, where i am today professor of cell biology, my lab discovered and analyzed necroptosis, a regulated necrotic cell death mechanism. I have received many honors and awards for my work and am a fellow of both the american academy of arts and sciences and the american association for advancement of reflects research conducted from november 2006 through january mental therapeutics (click to expand). Ludwig center director, i am able to leverage this unique support with our national cancer institute-supported comprehensive cancer center, in which i serve as one of the associate directors for clinical science, to innovate and accelerate the best translational and clinical research in cancer across the harvard medical school-affiliated hospitals and research laboratories. All of the harvard teaching hospitals and clinics coordinate clinical cancer research through a single institutional review board and regulatory process, and this matrix allows a uniquely powerful tool to conduct innovative translational research and clinical trials at our dana-farber/harvard supported as an active unit for clinical discovery in our ludwig center, the early drug development center at dana-farber features more than 30 actively enrolling phase i and pilot proof-of-mechanism clinical trials of novel anti-cancer agents such as signal transduction inhibitors, other targeted thereapies and monoclonal antibodies, angiogenesis inhibitors, and cell cycle inhibitors.
We offer early stage clinical trials to patients with a wide variety of solid tumors and serve as a platform for collaborating research faculty from across the harvard system. We work collaboratively with other disease and research centers within dana-farber, as well as with phase i clinical teams at massachusetts general hospital and beth israel deaconess medical center, facilitating the exchange of knowledge and training a and bone oncology (click to expand). The discovery of the first oncogene, v-src, which is an aberrant tyrosine kinase, represents an example of a sarcoma-related discovery with broad implications for cancer therapeutics. Therefore, we centralize the care and research on these rare but highly informative one of the largest sarcoma centers in the world, seeing more than 1,000 new referrals of sarcoma patients each year, we have a multidisciplinary team of laboratory researchers and investigative physicians working together to bring new discoveries to clinical therapeutics, and to bring clinical observations in these unique patients back to the laboratory for mechanistic linking all of the harvard-associated hospitals, including adult and pediatric oncology researchers, we bring a unique focus to the experimental therapeutics research focus of the ludwig center at al immuno-oncology (click to expand). Explosion in activity and interest in therapeutic modulation of the human immune system as an anticancer therapeutic strategy has been extraordinary in the past five years. Research at ludwig and dana-farber has paved the way for the current advances over the past 50 years. To ensure the continued connection between laboratory discoveries and experimental therapeutics in this field, a new center for clinical immuno-oncology was begun at dana-farber/harvard in 2012, with the vision of establishing a highly focused unit for clinical discovery as part of our ludwig center. Stephen hodi, and with the scientific input of ludwig professor lee nadler, glenn dranoff, and many others, this center serves to nurture and enable the most innovative and efficient translation of immunologic discoveries into into clinical interventions for patients with many different forms of ed cancer therapies (click to expand). To achieve this we have been taking a multifaceted approach, combining mouse modeling techniques with basic biochemical and cell biological of the most commonly deregulated signaling pathways in human cancer is the ras pathway. We have been focusing on how this pathway promotes melanoma and nervous system, lung, prostate and breast cancers. We have also been using our mouse models and insight to develop novel therapies, several of which have been developed into clinical ping novel combination therapies for ras-driven has been significant progress in developing targeted therapies for cancers driven by mutations in genes that encode enzymes (e. Developing effective therapies for cancers that are driven by mutations that do not directly affect a targetable protein is a major challenge in cancer research. We have been taking innovative approaches to develop novel combination therapies for ras-driven tumors and have recently made important advances in developing potential therapies for nervous system malignancies and lung cancer. We are now working to expand these efforts to prostate cancer and ering a growing family of tumor and metastasis rapidly evolving area of our research relates to identifying a new family of human tumor suppressors. Although mutations in ras genes are common in many cancers, ras mutations are conspicuously rare in breast, prostate and brain tumors, suggesting that ras is activated via alternative mechanisms. Our efforts revolve around understanding how these genes might play a role in mediating resistance to specific ling the expanding role of the nf1 tumor suppressor in cancer and drug resistancenf1 was the first rasgap gene shown to function as a human tumor suppressor. We and others have found that the nf1 gene is also mutated in a variety of sporadic cancers, including glioblastoma, melanoma and lung cancer. We are using these models to elucidate the mechanisms of tumor pathogenesis and develop new, targeted cancer etics and the ras pathway: identifying new therapeutic deregulation of epigenetic processes is rapidly becoming appreciated as an important regulator of cancer. Thus, in addition to unraveling new mechanisms that contribute to tumorigenesis, these findings reveal additional genes/proteins that represent new potential therapeutic 2ip inactivation promotes prostate cancer metastasis: an epithelial to mesenchymal transition (emt) is thought to mediate metastasis. Research has an extensive track record working to advance the understanding of lung cancer pathogenesis and to uncover new potential treatment. Discovering novel genetic alterations in human lung cancer that are important in lung cancer initiation, progression and acquired resistance to novel therapeutics that are initially h a series of mouse genetic experiments, we have identified serine/threonine kinase 11 (also known as lkb1) as a critical barrier to pulmonary tumorigenesis that controls initiation, differentiation and metastasis. Generating and characterizing genetically engineered mouse models that are based on novel lung relevant human genetic alterations to genetically validate the importance of these mutations and for preclinical testing of targeted have developed and characterized genetically engineered inducible mouse models of lung cancer based on the major lung cancer relevant oncogenic mutations in egfr, braf, pi3k3a, her2 and alk. Pioneering the concept of using genetically engineered mouse lung cancer models to conduct murine co-clinical trials to better inform and interpret ongoing human lung cancer clinical have performed a proof-of-concept experiments to show the utility and advantages of performing concurrent mouse co-clinical trials that mirror ongoing human clinical trials. Thus, co-clinical trials might accelerate the clinical development of novel cancer a complete list of joan brugge's publications, click a complete list of george d. Demetri's publications, click ve reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancerbrown kk, spinelli jb, asara jm, toker a. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. 2016 dec 15;76(24): promotes luminal differentiation and acts as a survival factor for er-positive breast cancer cellsbuchwalter g, hickey mm, cromer a, selfors lm, gunawardane rn, frishman j, jeselsohn r, lim e, chi d, fu x, schiff r, brown m, brugge js. Pdef promotes luminal differentiation and acts as a survival factor for er-positive breast cancer cells.
Murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responsea murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Cancer cell vulnerabilities to develop a combination therapy for ras-driven cancersde raedt t, walton z, lucas j, li d, chen y, maertens o, jeong sm, bronson rt , normant e, marcia c. Cancer cell (2011) 20(3):somal and genetic inactivation of the nf1 tumor suppressor in gliomagenesismcgillicuddy lt, beroukhim r, fromm ja, de raedt t, hollstein pe, johnson bw, nghiemphu l, liau lm, cloughesy tf, mischel ps, debiec-rychter m, stemmer-rachamimov ao, sawyers cl, messiaen l, mellinghoff ik, cichowski k. Cancer cell (2009) 16(1): impact of human egfr kinase domain mutations on lung tumorigenesis and in vivo sensitivity to egfr targeted therapiesji h, li d, chen l, shimamura t, kobayashi s, mcnamara k, mahmood u, mitchell a, sun y, al-hashem r, chirieac l. 2010 jun 15;17(6):tion of pi3k/mtor leads to adaptive resistance in matrix-attached cancer cellsmuranen t, selfors lm, worster dt, iwanicki mp, song l, morales fc, gao s, mills gb, brugge js. Vulnerability in triple-negative breast cancer could improve treatment t follow-up of survival after treatment with nivolumab reported at aacr annual meeting scientists named to thomson reuters’ list of world’s most influential scientific minds. Df/hccdana-farber/harvard cancer center (df/hcc), an nci-designated comprehensive cancer center, was founded to integrate and build upon the collective talent and resources of the harvard cancer research community. Five boston academic medical institutions—beth israel deaconess medical center, boston children’s hospital, brigham and women’s hospital, dana-farber cancer institute, and massachusetts general hospital—and two harvard schools—the harvard medical school and the harvard t. Df/hcc is the powerful successor organization to the dana-farber cancer institute comprehensive cancer center, one of the original cancer centers designated by the nci in , more than 1,100 df/hcc cancer researchers are working together in innovative clinical-, translational-, basic-, and population-based research programs. Thousands of patients are being enrolled in our clinical one of the largest cancer research enterprises in the world, df/hcc is committed to maximizing the impact of its research for cancer patients and ultimately realizing a world without _glimcher@_livingston@_memmott@_pellman@ associate lf@@ associate go@ associate _nadler@ associate _ritz@_howley@tive to eliminate cancer pp@ associate @ associate ng and wski@ associate @ associate _nadler@ associate y_rebbeck@en@tt@@_zhao@ care delivery _schrag@g@_harper@@ia_polyak@@@_park@@fe@@_sharpe@_wucherpfennig@ risk and _viswanath@y_frazier@am@pmental _kufe@ey_shapiro@intestinal mo@ul@m_kaelin@in_ebert@_look@lf@ly_stegmaier@@a@et_shipp@h_anderson@n_hodi@s_stiles@@o_loda@@@al y@ma@@_ritz@orative functional nie_mohr@nie_mohr@ping and genetics for population @_viswanath@ael_gray@ogy specimen _bartel@ _howley@lized and data _london@ microarray and imaging stration drew memmott associate director for administration (617) 632-3488 email amanda smith executive assistant to drew memmott (617) 632-3487 email mary nunes df/hcc administrative specialist (617) 632-6198 email communications richard oakley communications manager (617) 632-4276 email danielle coller communications coordinator (617) 632-5756 email core facilities michelle cox senior director for core facilities (617) 632-3566 email rachel goldblatt program manager (617) 632-2587 email informatics thomas leonard web systems architect (617) 632-3937 email initiative to eliminate cancer disparities karen burns white deputy associate director (617) 632-3244 email membership, program coordination, and operations deborah goff deputy associate director for program and operations support (617) 632-4044 email jackie hwang program manager (617) 632-5685 email erica fletcher grant administrator (617) 632-4864 email for clinical trials administration contact information, visit the clinical research patients and patients and for a loved nce & financial ments, centers, & y and nce & financial tments & second tments & second second opinion ational patients. 18/2017 11:06:11 's take the next steps cortical disorders, cancers, marrow failure, tumors, trial (uterine) intestinal carcinoid intestinal stromal tumor (gist). Cell tumors, ional trophoblastic cytosis, cancer, cancer, cell (oral cavity) ysplastic/myeloproliferative lastoma, ndocrine/carcinoid tumors, ry gland cancers (non-melanoma). Tissue sarcomas, h (gastric) (laryngeal) a/thymic d cancer, ström’s le an appointment today. Speak with a specialist 'll guide you through every step of planning your a second e our online second opinion service to get expert advice from dana-farber er the dana-farber over 70 years, we've led the world by making life-changing breakthroughs in cancer research and patient care, providing the most advanced treatments lists in your ing cancer is our sole mission. At dana-farber, you not only get a cancer specialist, but you also get a specialist in your particular type of unclassified tumor with a precisely targeted en-year-old jesus traveled from puerto rico for a successful experimental therapy that targets a rare genetic abnormality in his g barry’s body beat given two years to live, barry is now thriving — with the help of an immunotherapy drug developed by researchers at alizedfor youfrom an individualized treatment plan that recognizes who you are, to specialized therapies based on the genetic profile of your specific cancer — everything we do is centered around your unique care teamspecialized centerspatient & family support servicescounselingnutrition servicesintegrative therapiesyour care teampatients of every age need care tailored to their needs. Your care teamspecialized centerswe care for adults and children with cancer in our specialized treatment centers, focused on specific cancer types. Our teams of specialists work closely together to offer patients the latest therapies and clinical services, including access to innovative clinical ent centers and clinical servicespatient & family support serviceswe understand that cancer affects patients and their families in many ways. We offer a wide range of services, from financial planning to creative arts to spiritual care and more, to support our patients through their cancer t services for patients and familiescounselingpatients and their loved ones often face many new concerns and anxieties following a cancer diagnosis. Dana-farber’s team of social workers, psychologists, psychiatrists, and other staff work with patients, families, and other members of the health care team to provide integrated care and support for each patient’s unique worksupport groupsadult psychosocial oncologypediatric psychosocial oncologyspiritual carenutrition servicesnutrition experts at dana-farber will help you follow a healthy diet during and after your cancer treatment. Zakim center for integrative therapies and healthy living at dana-farber is dedicated to enhancing the quality of life for cancer patients and their families by incorporating complementary therapies — including acupuncture, massage, reiki, meditation, creative arts, and movement classes — into traditional cancer center programsexpressive arts precision medicine, pioneering young patient teaches veteran allison's brain tumor didn't respond to traditional treatments, dr. Today allison is doing tion means better care breaking clinicians — medical oncologists, surgeons, radiation oncologists, radiologists, pathologists, and nursing staff — have deep experience treating your particular type of cancer. Our team approach to cancer care ensures that you will receive the combination of treatments that is best for of the nation's top-rated cancer hospitals for adults and breaking -farber cancer institute remains true to dr. Sidney farber's vision of a cancer center that is as dedicated to discoveries in cancer research as it is to delivering compassionate, patient-centered care. Discoveries made by dana-farber researchers today become tomorrow’s breakthrough ch at ting scientific leaders at the cutting edge of cancer ch that -farber physicians and researchers have helped develop many of the very latest therapies — from harnessing the immune system to targeted therapies based on the genetics of your cancer. Which means we can provide the latest and best care, our 830 clinical ents & -farber president and ceo recognized for excellence at aamc annual wing therapy: how can it help cancer patients? Giving hand massages to cancer patients helps them – and me, ative ng cancer by location or genetic markers: which is better? Local woman opens her home to a fellow cancer prostatic hyperplasia (bph) and prostate cancer: what’s the difference? Every gift helps to advance our progress in the fight against jimmy fund supports dana-farber, raising funds to help cancer patients and their families around the world.